help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by La Rocca, R. V.
Right arrow Articles by Myers, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by La Rocca, R. V.
Right arrow Articles by Myers, C. E.

Journal of Clinical Endocrinology & Metabolism, Vol 71, 497-504, Copyright © 1990 by Endocrine Society


ARTICLES

Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect

RV La Rocca, CA Stein, R Danesi, CA Jamis-Dow, GH Weiss and CE Myers
Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

Suramin, a drug known to have antiparasitic effects, has been previously shown to have adrenocorticolytic activity in primates. We now confirm preferential accumulation of this compound in the normal adrenal gland, evaluate its in vitro effect against two human adrenocortical carcinoma cell lines (SW-13 and NCI-H295), and report the clinical activity of suramin in 17 patients with metastatic adrenocortical carcinoma. Inhibition of colony formation occurred in both adrenal cell lines in vitro at concentrations that are clinically achievable in humans. In addition, suramin concentrations as low as 100 micrograms/mL were able to inhibit glucocorticoid, mineralocorticoid, and androgen production by the NCI-H295 cell line. Of 16 patients with adrenocortical carcinoma now evaluable for tumor response, 2 achieved a partial response, 2 had a minor response, and 5 remained with stable disease for periods ranging from 3-10 months; the remainder progressed. One of 7 patients with excessive steroid hormone production achieved a partial normalization of her steroid levels for the duration of suramin therapy in the setting of radiographic disease stabilization. An additional patient treated off-study for lack of radiographically measurable disease, achieved complete normalization of plasma aldosterone levels. We conclude that suramin preferentially accumulates in adrenal cells, induces cytotoxicity and significant down-regulation of steroid hormone production in vitro, and has some therapeutic efficacy as a single agent in patients with metastatic adrenocortical carcinoma.


This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
D E Schteingart, G M Doherty, P G Gauger, T J Giordano, G D Hammer, M Korobkin, and F P Worden
Management of patients with adrenal cancer: recommendations of an international consensus conference
Endocr. Relat. Cancer, September 1, 2005; 12(3): 667 - 680.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. H. Palamakumbura, S. Jeay, Y. Guo, N. Pischon, P. Sommer, G. E. Sonenshein, and P. C. Trackman
The Propeptide Domain of Lysyl Oxidase Induces Phenotypic Reversion of Ras-transformed Cells
J. Biol. Chem., September 24, 2004; 279(39): 40593 - 40600.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. H. Palamakumbura, P. Sommer, and P. C. Trackman
Autocrine Growth Factor Regulation of Lysyl Oxidase Expression in Transformed Fibroblasts
J. Biol. Chem., August 15, 2003; 278(33): 30781 - 30787.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. P. Schneider, R. Salcedo, H. F. Dong, H. K. Kleinman, J. J. Oppenheim, and O. M. Z. Howard
Suradista NSC 651016 Inhibits the Angiogenic Activity of CXCL12-Stromal Cell-derived Factor 1{alpha}
Clin. Cancer Res., December 1, 2002; 8(12): 3955 - 3960.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. A. Kruger and W. D. Figg
Protein Binding Alters the Activity of Suramin, Carboxyamidotriazole, and UCN-01 in an ex Vivo Rat Aortic Ring Angiogenesis Assay
Clin. Cancer Res., July 1, 2001; 7(7): 1867 - 1872.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society